Table 2.

Changes of clinical endpoints from baseline to week 24

Endpoint	Placebo (n = 82)	Neflamapimod (n = 78)	Difference in change (95% CI)	P value
HVLT-R combined Z-score Total and Delayed Recall	−0.13 (−0.27, 0.01)	−0.17 (−0.38, 0.05)	−0.03 (-0.23, 0.16)	NS
WMS Immediate & Delayed Recall	16.6 (11.1, 22.1)	16.0 (10.5, 21.5)	-0.6 (−6.0, 4.8))	NS
CDR-SB	1.0 (0.5, 1.5)	1.1 (0.6, 1.7)	0.1 (−0.4, 0.6)	NS
MMSE	−0.5 (−1.3, 0.3)	−0.8 (−1.7, 0.1)	−0.3 (−1.0, 0.5)	NS

Except for MMSE, results shown derived from mixed model for repeated measures (MMRM) analysis of change from baseline to week 24. MMSE results from ANCOVA of change from baseline to week 24. Least square means (95% confidence interval) from models are shown